Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To compare outcomes in Sapien 3 Ultra (S3U) transcatheter aortic valve replacement (TAVR) with extreme annular undersizing (EAU) versus nominal annular sizing (NAS).
Background: The Edwards S3U valve has reduced paravalvular leak (PVL) in TAVR but outcomes remain unknown in extremely undersized anatomy. Implanting a smaller S3U valve may facilitate future redo-TAVR but risk compromising hemodynamics.
Methods: From December 2019 to July 2021, 366 patients with native aortic stenosis underwent S3U TAVR. Patients with EAU (annular areas >430 mm for 23 mm or >546 mm for 26 mm) were compared to NAS (338-430 mm for 23 mm or 430-546 mm for 26 mm). In-hospital and 30-day outcomes, and redo-TAVR feasibility were determined.
Results: There were 79 (21.6%) EAU patients, with more bicuspid (p = 0.0014) and ≥moderate annular/left ventricular outflow tract calcification (p < 0.001). The EAU group had less annular oversizing than NAS group (23 mm: -8.2 ± 2.6% vs. 4.0 ± 7.0%, p < 0.001; 26 mm: -8.9 ± 2.2% vs. 6.7 ± 6.9%, p < 0.001), more balloon overfilling (71.3% vs. 11.6%, p < 0.001), and postdilatation (15.0% vs. 5.8%, p = 0.016). No differences were found in in-hospital or 30-day mortality and stroke (p > 0.05). Mild PVL (13.4% EAU vs. 11.5% NAS, p = 0.56) and mean gradients (23 mm: 13.0 ± 4.5 vs. 14.1 ± 5.4 mmHg, p = 0.40; 26 mm: 11.4 ± 4.1 vs. 11.5 ± 3.9 mmHg, p = 1.0) were similar at 30 days. Had the EAU group undergone NAS with the larger Sapien 3/S3U, by computed tomography analysis simulating 80:20 or 90:10 target implant depth, 33.3%-60.9% (vs. 4.3%-23.2%) would not be feasible for redo-TAVR due to high risk of coronary obstruction.
Conclusions: In this first report of EAU with S3U TAVR, similar excellent short-term outcomes can be achieved compared to NAS, and may preserve future redo-TAVR option.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ccd.30146 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States.
JACC Cardiovasc Interv
August 2025
Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, Missouri, USA.
Background: Aortic valve-in-valve (AViV) replacement for is approved for patients with degenerated surgical valves at high or prohibitive surgical risk, mostly on the basis of small series with short-term follow-up.
Objectives: The aim of this study was to analyze the outcomes of AViV therapy using contemporary balloon-expandable valves (BEVs) in a large series with mid-term outcomes.
Methods: BEV AViV patients (June 2015 to December 2023) in the Society for Thoracic Surgeons (STS)/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry were propensity matched to native transcatheter aortic valve replacement (TAVR) patients.
Single- Versus Dual-Access Transcatheter Aortic Valve Implantation Using Balloon-Expandable Platform: A Propensity Score Matching Study.
JACC Adv
August 2025
Cardiothoracic Centre, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom. Electronic address:
Background: Vascular complications are more frequently encountered in patients undergoing transcatheter aortic valve implantation (TAVI) compared to surgical aortic valve replacement. Single access (SA) TAVI may reduce access-site complications, but this approach has not been widely studied.
Objectives: The aim of the study was to compare clinical outcomes of SA vs dual access (DA) TAVI using balloon-expandable valve Sapien 3 Ultra.
Dynamic Tamponade as Treatment: First-in-Human Conservative Approach to Post-TAVI Annular Rupture.
Catheter Cardiovasc Interv
August 2025
Department of Cardiothoracic Surgery, Derriford Hospital, University Hospitals Plymouth, Plymouth, UK.
Annular rupture is a rare but catastrophic complication of transcatheter aortic valve implantation (TAVI), often necessitating emergent surgical intervention. In patients deemed unsuitable for surgery, alternative conservative strategies must be considered. We report the case of a 77-year-old woman with severe calcific aortic stenosis who underwent transapical TAVI using a 20 mm Sapien S3 Ultra valve.
View Article and Find Full Text PDFDurability Testing With Calcification of Surgical Aortic Valves and Transcatheter Heart Valves: An In Vitro Study.
Interdiscip Cardiovasc Thorac Surg
September 2025
Department of Cardiac and Thoracic Vascular Surgery, University-Medical-Center Schleswig-Holstein, Campus Luebeck, Lubeck, 23562, Germany.
Objectives: Structural valve deterioration, mainly caused by calcification, is the Achilles heel of the bioprosthetic heart valves. While clinical long-term experience of surgical aortic valve (SAV) bioprostheses exists, transcatheter heart valve (THV) requires further investigations into biological degeneration. Therefore, this in vitro study aimed to analyse the calcification pattern of different SAV and THV models under standardized conditions.
View Article and Find Full Text PDFEarly Hemodynamic Performance of the SAPIEN 3 Ultra Resilia and Evolut Valves: A Propensity-Matched Analysis.
Can J Cardiol
August 2025
Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Clinic Barcelona, Barcelona, Spain. Electronic address:
Background: Limited data are available on early hemodynamic outcomes of the balloon-expandable SAPIEN 3 Ultra Resilia (S3UR) from Edwards Lifesciences (Irvine, CA) compared with the self-expandable Evolut (Medtronic, Dublin, Ireland) transcatheter heart valves. In this study we aimed to compare the hemodynamic performance of the S3UR with contemporary Evolut platforms (Evolut PRO, PRO+, FX) in a propensity-matched study.
Methods: A total of 307 patients who received an S3UR valve were matched with 488 patients who received Evolut valves (mean age, 80.